For patients with severe renal impairment, whilst effective chemotherapy can rapidly reduce FLC production, the half-life of the sFLCs will be prolonged and chemotherapy alone may not lead to an immediate reduction in sFLC concentrations. In such patients, it is tempting to think that strategies for direct removal of FLC will accelerate renal recovery. Plasma exchange, high-cut-off haemodialysis and adsorption have all been trialled as mechanisms for FLC removal; the results are discussed in detail below. Recent recommendations from the IMWG state that current data supports the use of HCO haemodialysis or plasma exchange (in combination with antimyeloma therapy) for selected patients with acute renal impairment due to MM cast nephropathy .
27.4.1. Plasma exchange
In the largest randomised control trial of plasma exchange that included 107 patients with severe AKI associated with MM, Clark et al.  failed to demonstrate any benefit of plasma exchange for either renal recovery or overall patient survival. However, renal biopsy information was not available for all patients in the trial (so a diagnosis of cast nephropathy was not established) and sFLCs were not measured. Regarding the lack of sFLC measurement, a subsequent editorial in the Journal of the American Society of Nephrology  commented “This resembles anti-hypertensive treatment without measuring blood pressure.” Clearly, the efficiency of plasma exchange for FLC removal could not be judged.
In a small study of 18 patients with biopsy-proven cast nephropathy, who were treated with bortezomib and plasma exchange, Leung et al.  concluded that patients were more likely to recover renal function if a 50% reduction in sFLC concentrations was achieved. For patients with pathologies other than cast nephropathy, the recovery of renal function did not depend on sFLC reduction, emphasising the necessity for biopsy confirmation of cast nephropathy when interpreting trial data. developed a compartmental mathematical model that was applicable to patients being treated for MM and renal failure. The following parameters were included: 1) sFLC concentrations at clinical presentation; 2) monomeric κ and dimeric λ clearance rates with and without renal failure; 3) partition of sFLCs between vascular and extravascular compartments (including oedema fluid); 4) flow of FLCs between compartments; 5) half-life of sFLCs in renal failure; 6) sFLC production rates; and 7) tumour killing rates with chemotherapy. Figure 27.3 displays the calculated clearance of κ FLCs in a light chain MM (LCMM) patient with renal failure treated with chemotherapy (assuming 10% tumour kill per day, Line 2). Addition of 6 plasma exchange treatments over 12 days is shown Figure 27.3, Line 3), and the rapid reductions in sFLC concentrations during the procedure and their subsequent re-entry from the extra-vascular to the intra-vascular compartment can be observed. Plasma exchange increased removal rates by approximately 25% but concentrations were not reduced below toxic levels (500 mg/L) at 4 weeks. Therefore, the lack of success of plasma exchange may be explained by the limited duration and frequency of this procedure, combined with on-going high production rates due to ineffective chemotherapy and re-entry of FLCs from extravascular compartments. . A 2011 report of 14 patients with biopsy-proven or high probability cast nephropathy (defined as sFLC >2000 mg/L), treated with a combination of bortezomib-based chemotherapy plus a median of 8 plasma exchanges, described good patient outcomes. A partial renal response (PRR) or better was achieved in 86% of patients (a PRR was defined as a >50% reduction in serum creatinine from the maximum value, or freedom from haemodialysis within 6 months among patients who were initially undergoing haemodialyisis) . The median time to the discontinuation of plasma exchange was 8 days (range 4 to 23) during which time the mean reduction in sFLCs was 74.6% (range 36.6 to 96.3%), and 6 patients had complete recovery of renal function within 6 months (Figure 27.4). However, this study did not include a control group so it was not possible to separate the efficacy of the chemotherapy from that of the plasma exchange.
27.4.2. High cut-off haemodialysis(Figure 27.5) . With high permeability for substances in the molecular weight range of 15 – 45 kDa, such membranes can effectively clear both κ and λ FLCs. Initial data suggested that the duration of haemodialysis could be safely extended allowing further reductions in sFLCs.  reported calculations from their mathematical model indicating that the prolonged daily use of HCO dialysers could rapidly reduce κ sFLC concentrations to less than 0.5 g/L in 2 - 3 days, equating to removal of around 95% of the total mass of sFLCs (Figure 27.3; Line 5). This preliminary publication also reported results from treating 5 newly-diagnosed MM patients with dialysis-dependent cast nephropathy . Figure 27.6 shows the rapid removal of λ FLCs in a patient with MM using the Gambro HCO 1100 dialysis membrane over a 6-hour period. Also shown are the large amounts of FLCs in the dialysate fluid. A total of nearly 40 grams of FLCs were removed in the single dialysis session. Sustained reductions in sFLC concentrations were observed in 3 patients who became independent of dialysis. Treatment examples are shown in Figure 27.7 and 27.8. The first of the figures shows good FLC reductions with recovery (Figure 27.7). In the second, the patient failed to achieve renal recovery (Figure 27.8). This patient developed sepsis and chemotherapy was stopped. Despite prolonged periods of haemodialysis and removal of 1.7 kg of FLCs, there was no recovery of renal function. It should be emphasised that for renal recovery to occur, patients needed both effective chemotherapy (to switch off FLC production) and rapid reduction of sFLCs. This is illustrated in Figure 27.9, in which a patient treated with HCO haemodialysis failed to respond to the initial chemotherapy but responded to bortezomib and subsequently recovered renal function.
A subsequent publication by Hutchison et al.  studied the effect of using two HCO 1100 dialysers in series, dialyser change, and haemodiafiltration on the efficiency of FLC removal. Based on the finding that the clearance rates of κ and λ FLCs increased when using two HCO 1100 dialysers in series, a new membrane, termed Theralite™, with a larger effective membrane area (2.1 m2) was developed.
Results from HCO haemodialysis trials have also been reported by other research groups. Khalafallah et al.  reported a series of four patients treated in Tasmania; the three de novo MM patients recovered renal function whilst the patient with relapsed disease did not. Five patients treated in Spain were the subject of a publication by Borrego-Hinojosa et al. . Four of the five became dialysis independent and from consideration of their results the authors suggested that early initiation of treatment could be a determining factor for the response. Tan et al.  reported a case series of six patients treated in New Zealand, of whom only three became dialysis independent and the authors concluded that the benefit of HCO dialysis was unproven.
Haemodialysis may not be effective if the patients’ plasma contains monoclonal FLCs that form large aggregates (Section 7.5). Harding et al.  described two patients with renal failure and MM for whom HCO haemodialysis was not effective in removing monoclonal sFLCs. Size exclusion chromatography demonstrated that a significant proportion of the tumour-produced sFLCs were in the form of large polymers. Such aggregates were too large to pass through the dialysis membrane.
Two large multicentre, prospective, randomised controlled trials, EuLITE and MYRE have been undertaken to determine whether HCO haemodialysis improves patient outcomes . Cook et al.  reported the findings of the EuLITE study, which compared HCO haemodialysis to standard high-flux haemodialysis in 90 patients with newly diagnosed MM and associated cast nephropathy, treated with bortezomib-based chempotherapy. At randomisation there was no difference in the sFLC levels between the HCO and high-flux groups. Following the first full protocol dialysis, a greater reduction in sFLC concentrations was observed for the HCO compared to the high-flux protocols (κ patients 75.6% vs 20.2%; λ patients: 71.2% vs 9.1%, p<0.001). However, after 3 weeks of treatment there was no difference in the reduction of sFLCs between the two groups, nor in the overall proportion of patients with renal recovery (HCO: 58.1%; high-flux: 66.0%). Unfortunately, HCO haemodialysis was associated with increased lung infections in the first 3 months (p=0.014) and a reduced overall survival at 2 years (55.8% and 76.6%, respectively). In summary, the EuLITE HCO protocol did not result in an improved outcome compared to standard high-flux dialysis, and the results of the MYRE study are now awaited.
Clinical case history
Resolution of cast nephropathy following FLC removal by haemodialysis .
Figure 27.13 . Despite this, the patient remained dialysis-dependent and a repeat renal biopsy was performed. The biopsy demonstrated resolution of waxy casts and partial resolution of the inflammatory infiltrate, but interstitial fibrosis and tubular atrophy was unchanged Figure 27.12B . After a further six dialysis sessions the patient was switched to a standard high-flux schedule. After a further 5 days the haemodialysis was discontinued in accordance with the patient’s wishes. Creatinine was 650 μm/L. One year on, the patient remains clinically well, with a maintained urine output and no uraemic symptoms despite having an eGFR of 8 ml/min/1.73 m2. The patient’s MM remains in remission.
In summary, this case illustrates how the sFLC assay can effectively monitor reductions in FLCs following treatment with chemotherapy and HCO haemodialysis. It also provides histological evidence that such reductions may be accompanied by resolution of intratubular casts.
27.4.3. Haemodialysis and adsorption
As an alternative to removal of sFLCs by HCO haemodialysis, strategies have been proposed that employ FLC adsorption or a combination of haemodialysis and adsorption. Polymethylmethacrylate (PMMA) membranes are routinely used to perform standard haemodialysis, but until recently their adsorption capacity for FLCs had not been well characterised. Fabbrini et al.  treated 10 patients with dialysis-dependent renal failure and high levels of monoclonal sFLCs (>500 mg/L) with at least one standard 4-hour dialysis session with a Toray BK 2.1 m2 PMMA membrane. The study concluded that PMMA haemodialysis reduced κ and λ sFLCs to a similar extent (concentrations were reduced by 22.3% and 21.0%, respectively), but that the process was limited by membrane saturation. Dialyser replacement after 2 hours (termed “enhanced adsorption dialysis”) increased the overall adsorption efficiency, particularly for λ FLCs . Santoro et al.  reported similar findings using two PMMA membranes in sequence (termed the “DELETE system”). An illustrative case is shown in Figure 27.14 .
A different strategy for FLC removal employed a plasma filter followed by a sorbent cartridge. This technique, known as coupled plasma-filtration adsorption (CPFA), has been used in the extracorporeal treatment of sepsis. In an in vitro study of FLC removal by CPFA using a number of different resins, the MDR3 resin demonstrated the best adsorptive capacity . For patients treated with at least six, 4-hour CPFA sessions using MDR3, sFLC concentrations progressively decreased (p=0.05), although the dialysis protocol remains to be optimised.
Another adsorption strategy has used “SUPRA HFR”, a form of haemodiafiltration with separated convection, diffusion and adsorption stages that avoids the albumin losses seen with other HCO haemodialysis protocols. The filter comprised an HCO membrane (Synclear 0.2), followed by a low-flux polyphenylene membrane in a second diffusive stage, and a sorbent cartridge with a high affinity for FLCs. Three patients with dialysis-dependent renal failure due to biopsy-proven cast nephropathy were successfully treated with SUPRA HFR . All patients showed a significant reduction of sFLCs and a complete recovery of renal function after 30, 50 and 90 days, respectively . Pasquali et al.  reported four further patients treated with this protocol, of whom three recovered renal function.